CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santoro, M.
Right arrow Articles by Fusco, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santoro, M.
Right arrow Articles by Fusco, A.

Cell Growth & Differentiation, Vol 4, Issue 2 77-84, Copyright © 1993 by American Association of Cancer Research

ARTICLES

The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line

M Santoro, RM Melillo, M Grieco, MT Berlingieri, G Vecchio and A Fusco
Dipartimento di Biologia e Patologia Cellulare e Molecolare L. Califano, II Facolta di Medicina e Chirurgia, Universita degli Studi di Napoli, Italy.

We have recently reported that about 50% of papillary thyroid carcinomas harbor an activated TRK or RET oncogene. Two retroviral vectors containing the activated TRK or RET/PTC oncogene have been used to infect a differentiated rat thyroid epithelial cell line, namely the PC Clone 3 cell line. Upon infection with the TRK virus, the PC Clone 3 cells lost only the ability to trap iodide and to express the thyroperoxidase gene. Conversely, when infected with the PTC virus, the PC Clone 3 cells completely lost all of their differentiated functions. However, both the PC-TRK and PC-PTC cell lines were unable to grow in soft agar, and they were not tumorigenic when injected into nude mice. A completely undifferentiated and malignant phenotype was obtained by the cooperation between the TRK or RET and the viral Ha-ras or Ki-ras oncogenes.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
P. Pallante, A. Federico, M. T. Berlingieri, M. Bianco, A. Ferraro, F. Forzati, A. Iaccarino, M. Russo, G. M. Pierantoni, V. Leone, et al.
Loss of the CBX7 Gene Expression Correlates with a Highly Malignant Phenotype in Thyroid Cancer
Cancer Res., August 15, 2008; 68(16): 6770 - 6778.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Akeno-Stuart, M. Croyle, J. A. Knauf, R. Malaguarnera, D. Vitagliano, M. Santoro, C. Stephan, K. Grosios, M. Wartmann, R. Cozens, et al.
The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells
Cancer Res., July 15, 2007; 67(14): 6956 - 6964.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Ciampi and Y. E. Nikiforov
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Endocrinology, March 1, 2007; 148(3): 936 - 941.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. Riesco-Eizaguirre and P. Santisteban
A perspective view of sodium iodide symporter research and its clinical implications.
Eur. J. Endocrinol., October 1, 2006; 155(4): 495 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev., August 1, 2006; 27(5): 535 - 560.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Pallante, R Visone, M Ferracin, A Ferraro, M T Berlingieri, G Troncone, G Chiappetta, C G Liu, M Santoro, M Negrini, et al.
MicroRNA deregulation in human thyroid papillary carcinomas.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 497 - 508.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G Riesco-Eizaguirre, P Gutierrez-Martinez, M A Garcia-Cabezas, M Nistal, and P Santisteban
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 257 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. G. Borrello, L. Alberti, A. Fischer, D. Degl'Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, et al.
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene
PNAS, October 11, 2005; 102(41): 14825 - 14830.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Mitsutake, J. A. Knauf, S. Mitsutake, C. Mesa Jr., L. Zhang, and J. A. Fagin
Conditional BRAFV600E Expression Induces DNA Synthesis, Apoptosis, Dedifferentiation, and Chromosomal Instability in Thyroid PCCL3 Cells
Cancer Res., March 15, 2005; 65(6): 2465 - 2473.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Venkateswaran, D. K. Marsee, S. H. Green, and S. M. Jhiang
Forskolin, 8-Br-3',5'-Cyclic Adenosine 5'-Monophosphate, and Catalytic Protein Kinase A Expression in the Nucleus Increase Radioiodide Uptake and Sodium/Iodide Symporter Protein Levels in RET/PTC1-Expressing Cells
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6168 - 6172.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. M. Melillo, A. M. Cirafici, V. De Falco, M. Bellantoni, G. Chiappetta, A. Fusco, F. Carlomagno, A. Picascia, D. Tramontano, G. Tallini, et al.
The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma
Am. J. Pathol., August 1, 2004; 165(2): 511 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Xu, R. M. Quiros, P. Gattuso, K. B. Ain, and R. A. Prinz
High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines
Cancer Res., August 1, 2003; 63(15): 4561 - 4567.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Wang, J. A. Knauf, S. Basu, E. Puxeddu, H. Kuroda, M. Santoro, A. Fusco, and J. A. Fagin
Conditional Expression of RET/PTC Induces a Weak Oncogenic Drive in Thyroid PCCL3 Cells and Inhibits Thyrotropin Action at Multiple Levels
Mol. Endocrinol., July 1, 2003; 17(7): 1425 - 1436.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. T. Kimura, M. N. Nikiforova, Z. Zhu, J. A. Knauf, Y. E. Nikiforov, and J. A. Fagin
High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma
Cancer Res., April 1, 2003; 63(7): 1454 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Carlomagno, D. Vitagliano, T. Guida, M. Napolitano, G. Vecchio, A. Fusco, A. Gazit, A. Levitzki, and M. Santoro
The Kinase Inhibitor PP1 Blocks Tumorigenesis Induced by RET Oncogenes
Cancer Res., February 1, 2002; 62(4): 1077 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Chiappetta, P. Toti, F. Cetta, A. Giuliano, F. Pentimalli, I. Amendola, S. Lazzi, M. Monaco, L. Mazzuchelli, P. Tosi, et al.
The RET/PTC Oncogene Is Frequently Activated in Oncocytic Thyroid Tumors (Hurthle Cell Adenomas and Carcinomas), but Not in Oncocytic Hyperplastic Lesions
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 364 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
F. Basolo, R. Giannini, C. Monaco, R. M. Melillo, F. Carlomagno, M. Pancrazi, G. Salvatore, G. Chiappetta, F. Pacini, R. Elisei, et al.
Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma
Am. J. Pathol., January 1, 2002; 160(1): 247 - 254.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. M. Melillo, M. Santoro, S.-H. Ong, M. Billaud, A. Fusco, Y. R. Hadari, J. Schlessinger, and I. Lax
Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade
Mol. Cell. Biol., July 1, 2001; 21(13): 4177 - 4187.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. A. Dissen, J. A. Parrott, M. K. Skinner, D. F. Hill, M. E. Costa, and S. R. Ojeda
Direct Effects of Nerve Growth Factor on Thecal Cells from Antral Ovarian Follicles
Endocrinology, December 1, 2000; 141(12): 4736 - 4750.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Salvatore, M. V. Barone, G. Salvatore, R. M. Melillo, G. Chiappetta, A. Mineo, G. Fenzi, G. Vecchio, A. Fusco, and M. Santoro
Tyrosines 1015 and 1062 Are in VivoAutophosphorylation Sites in Ret and Ret-Derived Oncoproteins
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3898 - 3907.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Gabriella De Vita, M. T. Berlingieri, R. Visconti, M. D. Castellone, G. Viglietto, G. Baldassarre, M. Zannini, A. Bellacosa, P. N. Tsichlis, A. Fusco, et al.
Akt/Protein Kinase B Promotes Survival and Hormone-independent Proliferation of Thyroid Cells in the Absence of Dedifferentiating and Transforming Effects
Cancer Res., July 1, 2000; 60(14): 3916 - 3920.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
M. A. Sortino, F. Condorelli, C. Vancheri, A. Chiarenza, R. Bernardini, U. Consoli, and P. L. Canonico
Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors
Mol. Endocrinol., January 1, 2000; 14(1): 124 - 136.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. A. Thomas, H. Bunnell, H. A. Cook, E. D. Williams, A. Nerovnya, E. D. Cherstvoy, N. D. Tronko, T. I. Bogdanova, G. Chiappetta, G. Viglietto, et al.
High Prevalence of RET/PTC Rearrangements in Ukrainian and Belarussian Post-Chernobyl Thyroid Papillary Carcinomas: A Strong Correlation between RET/PTC3 and the Solid-Follicular Variant
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4232 - 4238.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
R. M. Melillo, M. V. Barone, G. Lupoli, A. M. Cirafici, F. Carlomagno, R. Visconti, B. Matoskova, P. P. Di Fiore, G. Vecchio, A. Fusco, et al.
Ret-mediated Mitogenesis Requires Src Kinase Activity
Cancer Res., March 1, 1999; 59(5): 1120 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. H. Fischer, J. A. Bond, P. Taysavang, O. E. Battles, and D. Wynford-Thomas
Papillary Thyroid Carcinoma Oncogene (RET/PTC) Alters the Nuclear Envelope and Chromatin Structure
Am. J. Pathol., November 1, 1998; 153(5): 1443 - 1450.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Pandey, X. Liu, J. E. Dixon, P. P. Di Fiore, and V. M. Dixit
Direct Association between the Ret Receptor Tyrosine Kinase and the Src Homology 2-containing Adapter Protein Grb7
J. Biol. Chem., May 3, 1996; 271(18): 10607 - 10610.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1993 by the American Association of Cancer Research.